Holen Sie sich die Stockscreener-App
4.13
0.24%
0.010
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$4.12
Offen:
$4.1
24-Stunden-Volumen:
115.66K
Relative Volume:
0.86
Marktkapitalisierung:
$171.80M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$109.16M
KGV:
1.5986
EPS:
2.5835
Netto-Cashflow:
$-9.11M
1W Leistung:
+1.47%
1M Leistung:
-12.50%
6M Leistung:
+7.55%
1J Leistung:
+74.26%
1-Tages-Spanne:
$4.06
$4.17
1-Wochen-Bereich:
$3.89
$4.22
52-Wochen-Spanne:
$2.09
$5.47
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.13 | 171.80M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Barron's lists USD 7.00 target for Oramed Pharmaceuticals stock - AD HOC NEWS
Oramed Pharmaceuticals Inc (OJU1.DU) stock price, news, quote and history - Yahoo Finance UK
Oramed Pharmaceuticals schedules November 12 results for Oramed Pharmaceuticals stock - ad-hoc-news.de
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Oramed Pharmaceuticals stock fell 3.74 percent as targets rose - AD HOC NEWS
Oramed Pharmaceuticals Inc (OJU1.DU) stock price, news, quote and history - Yahoo Finance Australia
Form 4 Oramed Pharmaceuticals Inc For: 2 October By Investing.com - Investing.com Australia
Form 4 Oramed Pharmaceuticals Inc For: 2 October By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stock By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals (ORMP) CFO Avraham Gabay Sells 20,000 Sha - GuruFocus
Oramed COO & CBO Joshua Hexter sells $135,330 in shares By Investing.com - Investing.com Nigeria
Oramed COO & CBO Joshua Hexter sells $135,330 in shares By Investing.com - Investing.com South Africa
Form 4 Oramed Pharmaceuticals Inc For: 2 October By Investing.com - Investing.com India
Oramed COO & CBO Joshua Hexter sells $135,330 in shares - Investing.com
Oramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stock - Investing.com
A planned CFO sale at Oramed Pharmaceuticals (ORMP) totals 20,000 shares at an average $4.51. - Stock Titan
Under a trading plan, Oramed (ORMP) COO Joshua Hexter sells 30,000 shares at $4.511 on average. - Stock Titan
Form 4 Oramed Pharmaceuticals Inc For: 2 October By Investing.com - Investing.com UK
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 October By Investing.com - Investing.com Nigeria
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 October By Investing.com - Investing.com Canada
An officer proposes selling 20,000 Oramed (ORMP) shares under a preset trading plan. - Stock Titan
A trading plan underpins an officer's proposed $140K share sale at Oramed (ORMP). - Stock Titan
40% of Oramed (ORMP) CFO’s stock award vests at grant; the rest vests over 24 months. - Stock Titan
Six option grants were canceled in exchange for a fully vested stock award to Oramed (ORMP) CEO Nadav Kidron. - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to S&P Global BMI Index - marketscreener.com
Oramed Pharmaceuticals stock trades quietly as investors weigh recent trial progress - AD HOC NEWS
Oramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Detailed Stock Data - The Chronicle-Journal
Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com Nigeria
Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com UK
Oramed Pharmaceuticals (ORMP) moves to three-year pay votes - Stock Titan
Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting - Investing.com
Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Slips to $4.76, Holding Above $4.52 SupportIV Rank - careplusvn.com
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceConversion Trade - siam.in
Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness - Yahoo Finance
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayMid-Term Outlook - dars.gov.et
Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - Yahoo Finance
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oramed Pharmaceuticals Inc-Aktie (ORMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Avi Gabay | Officer |
Oct 01 '26 |
Proposed Sale |
4.67 |
20,000 |
93,400 |
0 |
| Hexter Joshua | COO & CBO |
Oct 01 '26 |
Sale |
4.51 |
30,000 |
135,330 |
1,328,130 |
| Joshua Hexter | Officer |
Oct 01 '26 |
Proposed Sale |
4.67 |
30,000 |
140,100 |
0 |
| Hexter Joshua | COO & CBO |
Jul 02 '26 |
Option Exercise |
3.69 |
50,000 |
184,500 |
1,073,384 |
| Hexter Joshua | COO & CBO |
Jul 01 '26 |
Sale |
4.46 |
137,000 |
611,431 |
1,023,384 |
| Gabay Avraham | Chief Financial Officer |
Jul 01 '26 |
Sale |
4.51 |
73,360 |
330,744 |
671,785 |
| Hexter Joshua | Officer |
Jul 01 '26 |
Proposed Sale |
4.81 |
137,000 |
658,970 |
0 |
| Gabay Avraham | Officer |
Jul 01 '26 |
Proposed Sale |
4.81 |
93,360 |
449,062 |
0 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
3.09%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):